Skip To Main Content
Chiara Bardella on Muck Rack

Chiara Bardella

As seen in: Nature, MDPI, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chiara

Contact Chiara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Addendum: Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche

|
By Hayley Davis, Shazia Irshad, Mukesh Bansal, Hannah Rafferty, Chiara Bardella, Emma Jaeger, Annabelle Lewis, Luke Freeman-Mills, Francesc Giner, Pedro Rodenas-Cuadrado, Sreelakshmi Mallappa, Susan Clark, Huw Thomas Verified, Richard Poulsom, Manuel Rodriguez-Justo, Marco Novelli, Runjan Chetty, Owen J. Sansom, Florian R. Greten, Lai Wang, James E East, Ian Tomlinson, Simon J. Leedham, Tatjana Boitsova, Rosemary Jeffery
| Nature Verified
Addendum to: Nature Medicine https://doi.org/10.1038/nm.3750, published online 1 December 2014. In the version of this article initially published, we reported paired immunohistochemical staining of Ki67 and CDKN2A/p16INK4A on serial sections of Vil1-Grem1 mouse polyps (Fig. 2e) and human traditional serrated adenomas (TSAs; Supplementary Fig. 7d), which we interpreted as showing loss of CDKN2A/p16INK4A expression in proliferating ectopic crypt cells.
Open in Who Shared Issue with article?

Mutant IDH in Gliomas: Role in Cancer and Treatment Options

|
By Alina Finch, Chiara Bardella, Georgios Solomou, Asim Asghar
| MDPI
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open in Who Shared Issue with article?

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors - Nature Communications

|
By Raphael Reinbold, Patrick Rabe, Ryan A. Herold, Alina Finch, James Wood, Melissa Morgan, Ian J. Clifton, Fraser A. Armstrong, Chiara Bardella, Christopher J Schofield, Ingvild C. Hvinden, Maximillian Staudt
| Nature Verified
Abstract Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1) R132C and R132H variants, is approved for the treatment of acute myeloid leukaemia (AML). Resistance to ivosidenib due to a second site mutation of IDH1 R132C, leading to IDH1 R132C/S280F, has emerged.
Open in Who Shared Issue with article?
See all 6 articles